Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab
about
Dabigatran approaching the realm of heparin-induced thrombocytopeniaDental management of patients taking novel oral anticoagulants (NOAs): Dabigatran.First Reported Case of Hemopericardium Related to Dabigatran Use Reversed by New Antidote Idarucizumab.Antiplatelet and Anticoagulant Therapies for Prevention of Ischemic Stroke.New Anticoagulants for the Prevention and Treatment of Venous Thromboembolism.New horizons in anticoagulation: Direct oral anticoagulants and their implications in oral surgery.Medication Reviews by a Clinical Pharmacist at an Irish University Teaching Hospital.Severe haematuria of lower urinary tract origin with low dose dabigatran use in three Indian elderly patients: unresolved issues in the safety of novel oral anticoagulants.Engineering a simple lateral flow device for animal blood coagulation monitoring.Reversal Agents in the Era of NOACs.Portal vein thrombosis in patients with cirrhosis: underdiagnosis and undertreatment?Newer Oral Anticoagulants in the Treatment of Acute Portal Vein Thrombosis in Patients with and without Cirrhosis.Portal vein thrombosis in cirrhotic patients - it is always the small pieces that make the big pictureComparison of reversal activity and mechanism of action of UHRA, andexanet, and PER977 on heparin and oral FXa inhibitors
P2860
Q26744261-D89E6A6D-AC7E-462A-9070-E1484FF9D1E3Q36283736-5D356B70-7B19-48E5-AAB7-2D882E9E7859Q38685055-3D2DFB47-A4CA-4490-8245-4BDF0EDE995CQ38909618-7770E423-A7B1-4694-8F75-5DC8F6B92B95Q39213540-EBB95BEA-E011-4039-8254-D651A32FC8F6Q47099414-49B8AD15-6478-4736-916A-699A7979EB15Q47232266-9524D060-E4A0-496F-9EC8-46DFE32E7C01Q49739706-ECA91984-3165-4C6F-BB76-05205CDB05FEQ50048280-37D6D33F-190B-4111-AAB5-C9E31D135CEFQ50333195-5E1DB87F-1436-4388-9FA9-ABD578E863B9Q53783646-CBBC482E-AFF1-4130-AA9D-079550EC49EAQ55442446-6B85A543-0DCA-4F81-B427-F96AD04389E6Q57807139-6DD29F13-BA47-4005-9BEE-C9D7E5FF983FQ58719429-79A1F564-2DE5-4B33-B028-876CF0F6C438
P2860
Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab
description
2016 nî lūn-bûn
@nan
2016 թուականին հրատարակուած գիտական յօդուած
@hyw
2016 թվականին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Reversing anticoagulant effect ...... dexanet alfa, and idarucizumab
@ast
Reversing anticoagulant effect ...... dexanet alfa, and idarucizumab
@en
Reversing anticoagulant effect ...... dexanet alfa, and idarucizumab
@nl
type
label
Reversing anticoagulant effect ...... dexanet alfa, and idarucizumab
@ast
Reversing anticoagulant effect ...... dexanet alfa, and idarucizumab
@en
Reversing anticoagulant effect ...... dexanet alfa, and idarucizumab
@nl
prefLabel
Reversing anticoagulant effect ...... dexanet alfa, and idarucizumab
@ast
Reversing anticoagulant effect ...... dexanet alfa, and idarucizumab
@en
Reversing anticoagulant effect ...... dexanet alfa, and idarucizumab
@nl
P2093
P2860
P921
P3181
P356
P1476
Reversing anticoagulant effect ...... dexanet alfa, and idarucizumab
@en
P2093
Samuel J Asirvatham
Tiffany Y Hu
Vaibhav R Vaidya
P2860
P3181
P356
10.2147/VHRM.S89130
P407
P577
2016-01-01T00:00:00Z
2016-02-17T00:00:00Z